CD22 and precursor B-cell acute lymphoblastic leukemia: Our study demonstrates that newly diagnosed B-ALL patients with very low levels of residual wildtype CD22 (“CD22E12low”), as measured by RNAseq-based CD22E12 mRNA levels, have significantly worse LFS as well as OS than other B-ALL patients.